MedTrace Logo

Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration

NCT01528605 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2014-08-29

Study results available
· View outcomes & findings →

Summary

This study is to investigate the protective effects of supplemental lutein and zeaxanthin on early age-related macular degeneration (AMD) patients in China.

Conditions

  • Age-related Macular Degeneration

Interventions

DIETARY_SUPPLEMENT

placebo

Placebo, one gelatine capsule containing starch per day, for 96 weeks

DIETARY_SUPPLEMENT

low lutein

one gelatine capsule containing 10mg lutein per day, for 96 weeks

DIETARY_SUPPLEMENT

high lutein

one gelatine capsule containing 20mg lutein per day, for 96 weeks

DIETARY_SUPPLEMENT

lutein plus zeaxanthin

one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks

DIETARY_SUPPLEMENT

high zeaxanthin

one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks

DIETARY_SUPPLEMENT

zeaxanthin plus lutein

one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks

Sponsors & Collaborators

  • Peking University

    lead OTHER

Principal Investigators

  • Xiaoming Lin, M.M. · Peking University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2012-09-30
Completion
2012-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01528605 on ClinicalTrials.gov